BridgeBio-JPM-2026-Presentation_vF.pdf

《BridgeBio-JPM-2026-Presentation_vF.pdf》由会员分享，可在线阅读，更多相关《BridgeBio-JPM-2026-Presentation_vF.pdf（48页珍藏版）》请在三个皮匠报告上搜索。

1、J.P.Morgan PresentationJanuary 12,2026 Forward Looking Statements and Disclaimer2The presentation contains forward-looking statements.Statements made or presented may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securiti

2、es Act of 1933,as amended,and Section 21E of the Securities Exchange Act of 1934,as amended.Words such as“believe,”“anticipate,”“plan,”“expect,”“intend,”“will,”“may,”“goal,”“potential,”“should,”“could,”“aim,”“estimate,”“predict,”“continue”and similar expressions or the negative of these terms or oth

3、er comparable terminology are intended to identify forward-looking statements,though not all forward-looking statements necessarily contain these identifying words.We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Secti

4、on 27A of the Securities Act and Section 21E of the Exchange Act.These forward-looking statements,including express and implied statements relating to the preliminary and unaudited estimate of cash resources as of December 31,2025 and the preliminary and unaudited estimate of net product revenue for

5、 Attruby for the quarter ended December 31,2025;the commercial success of Attruby;the clinical timeline and clinical and therapeutic potential for the new antibody depleter program for ATTR-CM;the timing and expectations regarding the status and progress of our various clinical trials,including data

6、 readouts for these trials;the safety,efficacy and mechanisms and the clinical,therapeutic and market potential of our clinical development programs and our pipeline,including infigratinib,BBP-418,encaleret and BBP-812;expected timing for submitting New Drug Applications with the U.S.Food and Drug A